Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

FDA delays final approval of the generic drug product until all patent issues are resolved.

This should read: “FDA delays final approval of the generic drug product until all patent issues are resolved or there is a Paragraph-IV challenge and the 30-month Hatch-Waxman stay has expired.”

Please see my reply to rwwine in #msg-76904920.